文献速递血栓与止血

多基因风险评分预测英国生物银行队列研究中癌症相关静脉血栓栓塞症

Polygenic risk scores for prediction of cancer-associated venous thromboembolism in the UK Biobank cohort study.
PubMed 文献 · J Thromb Haemost · 2023-07-20

在英国生物银行前瞻性队列的36150例癌症患者中,评估5、37、297、扩展297及100个SNP多基因评分预测癌症诊断后12个月内VTE的表现;12个月c指数从5-SNP的0.56至扩展297-SNP的0.60,扩展297-SNP的亚分布风险比为1.90,与Khorana肿瘤类型分类联合后c指数由0.60升至0.65。

要点

  • 扩展297-SNP评分预测12个月VTE的c指数为0.60,亚分布HR为1.90。
  • Khorana肿瘤类型分类c指数0.60,联合扩展297-SNP评分后升至0.65(+0.05)。
  • 多基因VTE风险评分可识别VTE风险高1.9倍且独立于肿瘤类型的癌症患者。

核心结论

  • 多基因VTE风险评分可识别VTE风险高1.9倍且独立于肿瘤类型的癌症患者。
  • 联合临床-遗传评分以改善癌症相关VTE预测应进一步评估。

研究设计与样本

  • 基于英国生物银行的人群前瞻性队列研究。
  • 纳入36150例癌症患者,中位年龄66岁,女性占48.7%。
  • 评估5、37、297、扩展297(额外包含因子V Leiden和凝血酶原G20210A)及100个SNP评分对癌症诊断后12个月内VTE的预测表现,并与Khorana肿瘤类型分类比较。

主要发现

  • 36150例癌症患者中1018例(2.8%)发生VTE。
  • 12个月c指数从5-SNP的0.56(95%CI 0.54-0.58)至扩展297-SNP的0.60(95%CI 0.58-0.62)。
  • 亚分布风险比从5-SNP的1.36(95%CI 1.19-1.56)至扩展297-SNP的1.90(95%CI 1.68-2.16),校正肿瘤类型后一致。
  • Khorana肿瘤类型分类c指数为0.60(95%CI 0.58-0.61),联合扩展297-SNP评分后升至0.65(95%CI 0.63-0.67,+0.05;95%CI 0.04-0.07)。

关键数值与推荐

  • 扩展297-SNP评分预测12个月VTE的c指数为0.60(95%CI 0.58-0.62),亚分布HR为1.90(95%CI 1.68-2.16)。
  • 5-SNP评分预测12个月VTE的c指数为0.56(95%CI 0.54-0.58),亚分布HR为1.36(95%CI 1.19-1.56)。
  • Khorana肿瘤类型分类c指数为0.60(95%CI 0.58-0.61)。
  • Khorana肿瘤类型分类联合扩展297-SNP评分后c指数为0.65(95%CI 0.63-0.67)。

临床怎么用

  • 原文结论提出联合临床-遗传评分以改善癌症相关VTE预测应进一步评估。

局限性

  • 原文结论提出联合临床-遗传评分以改善癌症相关VTE预测应进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend thromboprophylaxis for patients with cancer at high risk of venous thromboembolism (VTE). Polygenic risk scores may improve VTE prediction but have not yet been evaluated in patients with cancer. OBJECTIVES: We assessed the performance of the 5-, 37-, 297-, extended 297- (additionally including factor V Leiden and prothrombin G20210A), and 100-single-nucleotide polymorphism (SNP) scores in predicting cancer-associated VTE in the UK Biobank, a population-based, prospective cohort study. METHODS: The primary outcome was VTE during 12 months after cancer diagnosis. Cancer and VTE diagnosis were based on ICD-10 codes. Discrimination was evaluated by c-indices and subdistribution hazard ratios in the upper vs 3 lower quartiles of the scores in a competing risk model. As a comparison, the c-index was calculated for the Khorana cancer type risk classification. RESULTS: Of 36 150 patients with cancer (median age, 66 years; 48.7% females), 1018 (2.8%) developed VTE. C-indices at 12 months ranged from 0.56 (95% CI, 0.54-0.58) for the 5-SNP to 0.60 (95% CI, 0.58-0.62) for the extended 297-SNP scores. The subdistribution hazard ratios ranged from 1.36 (95% CI, 1.19-1.56) for the 5-SNP to 1.90 (95% CI, 1.68-2.16) for the extended 297-SNP scores and were consistent after adjusting for cancer type. For the Khorana cancer type classification, the c-index was 0.60 (95% CI, 0.58-0.61), which increased to 0.65 (95% CI, 0.63-0.67, +0.05; 95% CI, 0.04-0.07) when combined with the extended 297-SNP score. CONCLUSION: These findings demonstrate that polygenic VTE risk scores can identify patients with cancer with a 1.9-fold higher VTE risk independent of cancer type. Combined clinical-genetic scores to improve cancer-associated VTE prediction should be evaluated further.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Guman NAM, Mulder FI, Ferwerda B, et al. Polygenic risk scores for prediction of cancer-associated venous thromboembolism in the UK Biobank cohort study. J Thromb Haemost. 2023. PMID: 37481074. doi:10.1016/j.jtha.2023.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。